other material
confidence high
sentiment positive
materiality 0.65
Absci reports positive interim Phase 1 data for ABS-201; half-life ≥65 days supports dosing 2-3 times/6 months
Absci Corp
- No serious adverse events; TEAEs were mild except one moderate headache deemed unrelated to treatment.
- Estimated half-life of at least 65 days across all four SAD cohorts (150–1800 mg IV).
- MAD portion in androgenetic alopecia participants initiated; interim PoC data expected H2 2026.
- Phase 2 trial for endometriosis planned later this year.
- 32 healthy volunteers enrolled in four SAD cohorts; data cutoff June 8, 2026.